Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Drug Toxicity: Dose-Dependent Reactions

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Myocarditis I: Introduction

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Steroid-Refractory Immune Checkpoint Inhibitor-Induced Myocarditis Responsive to Mycophenolate and Antithymocyte Globulin.

JACC. Case reports·2025

Same author

Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.

JAMA cardiology·2023

Same author

Further Characterizing Cardiomyopathy Mortality in Young Adults to Elucidate Health Disparities.

JAMA cardiology·2022

Same author

Duchenne Muscular Dystrophy: the Heart of the Matter.

Current heart failure reports·2020

Same author

Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.

Journal of atrial fibrillation·2017

Same author

Apixaban in patients with Atrial Fibrillation: A Systematic Review.

Journal of atrial fibrillation·2017

Search research articles

Related Experiment Video

Updated: May 24, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced cardiotoxicity.

Amir Y Shaikh¹, Jeffrey A Shih

¹University of Massachusetts Memorial Medical Center, 55 Lake Avenue North, Worcester, MA, 01655, USA.

Current Heart Failure Reports

|March 3, 2012

Summary

Anthracycline chemotherapy can harm the heart. Dexrazoxane is a studied cardioprotective drug, but other agents and heart failure medications have unclear roles in preventing or treating chemotherapy-induced cardiotoxicity.

Area of Science:

Oncology
Cardiology
Pharmacology

Background:

Anthracycline chemotherapy is vital for treating many cancers.
A major limitation is significant cardiotoxicity, damaging heart muscle cells.
Preventive strategies focus on reducing free-radical damage to the heart.

Purpose of the Study:

To review the effectiveness of dexrazoxane in preventing anthracycline-induced cardiotoxicity.
To explore alternative cardioprotective agents and their potential cardiovascular risks.
To evaluate the established roles of beta-blockers and ACE inhibitors in heart failure and their potential, yet unproven, roles in chemotherapy-induced cardiotoxicity.

Main Methods:

Literature review of studies on anthracycline cardiotoxicity.
Analysis of clinical data on dexrazoxane efficacy and safety.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: May 24, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Examination of research on alternative cardioprotective agents.

Assessment of evidence regarding beta-blockers and ACE inhibitors in cardiovascular disease and chemotherapy contexts.

Main Results:

Dexrazoxane is the most extensively studied cardioprotective agent against anthracycline cardiotoxicity.
Alternative agents may offer some cardiotoxicity reduction but can introduce other cardiovascular issues.
The benefits of beta-blockers and ACE inhibitors for chemotherapy-induced cardiotoxicity are not well-established, despite their proven efficacy in heart failure.

Conclusions:

While dexrazoxane is a key cardioprotective strategy, its use and alternatives require careful consideration of cardiovascular risks.
Further research is needed to clarify the role of common heart failure medications in mitigating or treating chemotherapy-induced heart damage.